4,72 $
3,28 % gestern
Nasdaq, 7. Oktober, 15:30 Uhr
ISIN
US23254L4059
Symbol
CYCC
Berichte

Cyclacel Pharmaceuticals, Inc. Aktie News

Neutral
GlobeNewsWire
etwa 2 Monate alt
KUALA LUMPUR, Malaysia, Aug. 13, 2025 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines, today announced its second quarter financial results and provided a business update.
Neutral
GlobeNewsWire
2 Monate alt
- Biliary tract cancer (BTC) or cholangiocarcinoma is an aggressive tumor with poor prognosis - KUALA LUMPUR, Malaysia, Aug. 04, 2025 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative cancer medicines, highlighted a preclinical study from independent investigators titled, “ Evaluation ...
Neutral
GlobeNewsWire
3 Monate alt
- Fibrolamellar hepatocellular carcinoma (FLC) has no approved treatment and          occurs mostly in adolescents and young adults -
Neutral
GlobeNewsWire
3 Monate alt
Kuala Lumpur, Malaysia, July 07, 2025 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; “Cyclacel” or the “Company”), a biopharmaceutical company developing innovative medicines, today announced that it has entered into an amendment to the Exchange Agreement with FITTERS Diversified Berhad (9318.KL; “FITTERS”), an investment holding company engaged, through its su...
Neutral
GlobeNewsWire
3 Monate alt
BERKELEY HEIGHTS, N.J., July 02, 2025 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; “Cyclacel” or the “Company”), a biopharmaceutical company developing innovative medicines, today announced that it expects to implement a 1-for-15 reverse stock split on its shares of common stock effective July 7, 2025, with trading to begin on a split-adjusted basis at the ma...
Neutral
GlobeNewsWire
4 Monate alt
KUALA LUMPUR, June 20, 2025 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (“Cyclacel”) (NASDAQ: CYCC, NASDAQ: CYCCP), a biopharmaceutical company that develops innovative cancer medicine, today announced that it has entered into a securities purchase agreement for the sale of its convertible Series F Preferred Stock (“Preferred Stock”) in a private placement to certain accredited investors...
Neutral
GlobeNewsWire
4 Monate alt
KUALA LUMPUR, MALAYSIA, June 03, 2025 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; “Cyclacel” or the “Company”), a biopharmaceutical company that develops innovative cancer medicine, today announced that it has received a letter (the “Compliance Notice”) from the Listing Qualifications Department of The Nasdaq Stock Market Inc. (“Nasdaq”) dated June 3, 2025, ...
Neutral
GlobeNewsWire
5 Monate alt
KUALA LUMPUR, MALAYSIA, May 15, 2025 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines, today announced its first quarter financial results and provided a business update.

Kostenlos registrieren

aktien.guide ist das Tool zum einfachen Finden, Analysieren und Beobachten von Aktien. Lerne von erfolgreichen Investoren und triff fundierte Anlageentscheidungen. Wir machen Dich zum selbstbestimmten Investor.

Die Apple Aktie im Überblick mit Charts, aktuellen Kennzahlen, Nachrichten und Aktienanalysen.
Die besten Dividenden-Aktien in der Dividenden-Topscorer-Liste.
Aktienanalysen der besten Aktien weltweit.
Jetzt Vermögen aufbauen